ArticleBMC microbiology2013
Genetic diversity of clinical Pseudomonas aeruginosa isolates in a public hospital in Spain.
Article in BMC microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Assessing the Levels and Types of Bacterial Contamination in Cosmetic Brushes: Implications for Beauty and Hygiene in Jeddah City.International journal of microbiology · 2025Article
- Mitigating Health Risks Through Environmental Tracking of Pseudomonas aeruginosa.Current microbiology · 2024Review
- Deep longitudinal lower respiratory tract microbiome profiling reveals genome-resolved functional and evolutionary dynamics in critical illness.Nature communications · 2024Article
- Genomic Differences Associated with Resistance and Virulence inMicroorganisms · 2024Article
- Activity of Epsilon-poly-L-lysine against Multidrug-ResistantBiomedicines · 2024Article
- Genomic characterization of Pseudomonas spp. on food: implications for spoilage, antimicrobial resistance and human infection.BMC microbiology · 2024Article
- In Silico Study for Algerian Essential Oils as Antimicrobial Agents against Multidrug-Resistant Bacteria Isolated from Pus Samples.Antibiotics (Basel, Switzerland) · 2022Article
- Effect of Nanoencapsulation on the Antimicrobial and Antibiofilm Activities of AlgerianNanomaterials (Basel, Switzerland) · 2022Article
- Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.The Journal of antimicrobial chemotherapy · 2022Article
- Antimicrobial Resistance and Genomic Characterization of Six New Sequence Types in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed Pseudomonas aeruginosa Clonal Complex 446 in an Academic Medical Center.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Molecular Epidemiology of Carbapenemase-ProducingInfection and drug resistance · 2020Article
- A Core Genome Multilocus Sequence Typing Scheme forFrontiers in microbiology · 2020Article
- High frequency of the exoU+/exoS+ genotype associated with multidrug-resistant "high-risk clones" of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals.Scientific reports · 2019Article
- Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China.Bosnian journal of basic medical sciences · 2019Article
- The Inhibition Effect of Lactobacilli Against Growth and Biofilm Formation of Pseudomonas aeruginosa.Probiotics and antimicrobial proteins · 2018Article
- MULTILOCUS SEQUENCE TYPING OF CARBAPENEM RESISTANTAfrican journal of infectious diseases · 2017Article
- Identification of extensive drug resistant Pseudomonas aeruginosa strains: New clone ST1725 and high-risk clone ST233.PloS one · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa is an important nosocomial pathogen that exhibits multiple resistances to antibiotics with increasing frequency, making patient treatment more difficult. The aim of the study is to ascertain the population structure of this clinical pathogen in the Hospital Son Llàtzer, Spain.
resultsA significant set (56) of randomly selected clinical P. aeruginosa isolates, including multidrug and non-multidrug resistant isolates, were assigned to sequence types (STs) and compared them with their antibiotic susceptibility profile classified as follows: extensively drug resistant (XDR), multidrug resistant (MDR) and non-multidrug resistant (non-MDR). The genetic diversity was assessed by applying the multilocus sequence typing (MLST) scheme developed by Curran and collaborators, and by the phylogenetic analysis of a concatenated tree. The analysis of seven loci, acsA, aroE, guaA, mutL, nuoD, ppsA and trpE, demonstrated that the prevalent STs were ST-175, ST-235 and ST-253. The majority of the XDR and MDR isolates were included in ST-175 and ST-235. ST-253 is the third in frequency and included non-MDR isolates. The 26 singleton sequence types corresponded mainly to non-MDR isolates. Twenty-two isolates corresponded to new sequence types (not previously defined) of which 12 isolates were non-MDR and 10 isolates were MDR or XDR.
conclusionsThe population structure of clinical P. aeruginosa present in our hospital indicates the coexistence of nonresistant and resistant isolates with the same sequence type. The multiresistant isolates studied are grouped in the prevalent sequence types found in other Spanish hospitals and at the international level, and the susceptible isolates correspond mainly to singleton sequence types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.